Siltuximab: a new option for the management of Castleman's disease.

Castleman's disease is a rare lymphoproliferative disorder the underlying mechanism of which remains unclear. However, interleukin-6 (IL-6) may play a role in the pathogenesis of the disease. Blockade of the IL-6 pathway has been explored in multiple preclinical and clinical studies with promising results for the treatment of different types of cancer and Castleman's disease. Siltuximab is a human/murine chimeric immunoglobulin G1kappa (IgG1kappa) monoclonal antibody against human IL-6. It binds to IL-6 neutralizing its biological activity. Recent phase II clinical studies in patients with multicentric Castleman's disease have shown the efficacy and safety of siltuximab in patients with this condition. Results from this study led to the recent approval of siltuximab for the treatment of Castleman's disease by the FDA and EMA.

Barquero N 《DRUGS OF TODAY》

Siltuximab (CNTO 328): a promising option for human malignancies.

Chen R ，Chen B 《Drug Design Development and Therapy》

Siltuximab for multicentric Castleman disease.

Liu YC ，Stone K ，van Rhee F 《-》

Dose selection of siltuximab for multicentric Castleman's disease.

Mayer CL ，Xie L ，Bandekar R ，Qi M ，van de Velde H ，Reddy M ，Qin X ，Davis HM ，Puchalski TA ... -  《-》

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.

Mohammed A ，Janku F ，Qi M ，Kurzrock R ... -  《-》